Crocs Gets “Lit” This #CrocDay
22.10.2019 07:01:00 EEST | Business Wire | Press release
Crocs, Inc. (NASDAQ: CROX) a global leader in innovative, casual footwear for women, men and children, continues its annual Croctober celebration by partnering with premier streetwear brand Pizzaslime to deliver their latest, limited-edition, glow-in-the-dark version of the Classic Clog for Croc Day on Wednesday, October 23rd.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005886/en/
This year's limited edition #CrocDay Classic Clog will come fully loaded with a curated assortment of custom #CROCDAYISLIT Jibbitz™ charms — some of which glow! (Photo: Business Wire)
National Croc Day was adopted by brand fans as a way to celebrate all things Crocs with the shared hashtag #CrocDay. Last year’s limited-edition Croc Day shoe sold out within hours.
To commemorate this year’s event, the shoe will arrive fully-loaded with a curated assortment of custom, glow-in-the-dark #CROC DAY IS LIT Jibbitz™ charms – the first of their kind! Just as fun, each pair of #CrocDay shoes is available only as a mystery order that will include a UV light for an extra special surprise. Very lit. Very Rare.
“We wouldn’t be who we are without our loyal and passionate fan base who embody our mantra, ‘Come As You Are,’” said Terence Reilly, Crocs SVP and CMO. “Our fans have been celebrating Croctober around the globe and on Croc Day, I can’t wait to release these amazing, one-of-a-kind classic clogs. They are truly something special, and we’re excited to grow and glow together.”
“I don’t know how else to say it, Crocs are cool and have an extremely loyal following,” said Stoveman, co-creator of Pizzaslime. “They’re a brand that embraces individuality and self-expression like no other. That’s why we like working with them and why they’re popular in the streetwear space.”
This limited-edition style will be available globally on crocs.com for $59.99, beginning October 23rd at 10:23 a.m. in local times around the world (Eastern Standard Time in the US).
About Crocs, Inc.
Crocs, Inc. (Nasdaq: CROX) is a world leader in innovative casual footwear for women, men, and children, combining comfort and style with a value that consumers know and love. Crocs’ proprietary Croslite™ material, a molded footwear technology, is included in the vast majority of Crocs’ collection and delivers extraordinary comfort with each step.
In 2019, Crocs declares that expressing yourself and being comfortable are not mutually exclusive. To learn more about Crocs or our global Come As You Are™ campaign, please visit www.crocs.com or follow @Crocs on Facebook, Instagram and Twitter.
About Pizzaslime
Pizzaslime is an “outside of the box” brand that specializes in contextualizing the internet for the youth (gen z + millennials) through rapid-response viral products and original content. Chances are that your favorite artist or celebrity is a fan of the brand since it’s been spotted on pretty much everyone. Outside of being worn by some of the biggest names in pop culture Pizzaslime has also been featured by the NY Times, The Today Show, Vanity Fair, Hypebeast, Vice, Bon Appetit, Vogue, GQ, Bloomberg, and a bunch more. Behind the scenes, Pizzaslime also functions as a boutique creative and marketing studio for major record labels, big brands, movie studios, and artists. With a rabid audience built around the brand and a priceless network of celebrities, artists, and influencers, Pizzaslime is growing fast and people can’t get enough of it.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005886/en/
Contact information
Melissa Layton
Crocs, Inc.
mlayton@crocs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom